Demant A/S (OTCMKTS:WILYY) Reaches New 12-Month High – Here’s What Happened

Demant A/S Unsponsored ADR (OTCMKTS:WILYY)’s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $21.87 and last traded at $21.87, with a volume of 451 shares changing hands. The stock had previously closed at $19.25.

Analysts Set New Price Targets

A number of equities analysts have weighed in on WILYY shares. Zacks Research raised Demant A/S to a “hold” rating in a research note on Friday, June 26th. Morgan Stanley raised Demant A/S from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, June 23rd. Sanford C. Bernstein lowered Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. Finally, UBS Group cut shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Demant A/S Stock Performance

The company’s 50-day moving average price is $20.17 and its 200 day moving average price is $17.26. The company has a current ratio of 1.36, a quick ratio of 1.00 and a debt-to-equity ratio of 1.65.

About Demant A/S

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.